Novel De Novo Mutation in Sulfonylurea Receptor 1 Presenting as Hyperinsulinism in Infancy Followed by Overt Diabetes in Early Adolescence by Abdulhadi-Atwan, Maha et al.
Novel De Novo Mutation in Sulfonylurea Receptor 1
Presenting as Hyperinsulinism in Infancy Followed
by Overt Diabetes in Early Adolescence
Maha Abdulhadi-Atwan,
1 Jeremy D. Bushman,
2 Sharona Tornovsky-Babaey,
3 Avital Perry,
3
Abdulsalam Abu-Libdeh,
1 Benjamin Glaser,
3 Show-Ling Shyng,
2 and David H. Zangen
1
OBJECTIVE—Congenital hyperinsulinism, usually associated
with severe neonatal hypoglycemia, may progress to diabetes,
typically during the 4th decade of life in nonpancreatectomized
patients. We aimed to genotype the ATP-sensitive K
 channel in
a 10.5-year-old girl presenting with overt diabetes following
hyperinsulinism in infancy.
RESEARCH DESIGN AND METHODS—A female aged 10.5
years presented with new-onset, antibody-negative diabetes
(A1C 10.6%). She was born large for gestational age (5 kg) to a
nondiabetic mother and developed frequent hypoglycemic epi-
sodes, which persisted until age 3 years and responded initially to
intravenous glucose and later to oral sweets. Currently, she is
fully pubertal and obese (BMI 30.2 kg/m
2), with a partially
controlled convulsive disorder (since age 1 year) and poor school
performance. Glucose levels were 11.1 mmol/l throughout 72 h
of continuous glucose monitoring, with low insulin secretion
during intravenous glucose tolerance testing. KCNJ11 and
ABCC8 mutation analysis was performed, and the mutation
identiﬁed was characterized in COSm6 cells.
RESULTS—A novel, de novo heterozygous ABCC8 sulfonylurea
receptor (SUR)1 mutation (R370S) was identiﬁed in the patient’s
DNA but not in that of either parent. Cotransfection of Kir6.2 and
mutant SUR1 demonstrate that the mutated protein is expressed
efﬁciently at the cell surface but fails to respond to MgADP,
resulting in minimal channel activity. Interestingly, the heterozy-
gous channel (WT:R370S) responded well to glibenclamide, a
ﬁnding that lead to the successful initiation of sulfonylurea
therapy.
CONCLUSIONS—This new ABCC8 mutation is associated with
neonatal hyperinsulinism progressing within 10 years to insuli-
nopenic diabetes. Consistent with in vitro ﬁndings, the patient
responded to sulfonylurea treatment. The mechanism causing
the relatively rapid loss in -cell function is not clear, but it may
involve mutation-induced increased -cell apoptosis related to
increased metabolic demand. Diabetes 57:1935–1940, 2008
C
ongenital hyperinsulinism (CHI) is a disorder of
glucose metabolism characterized by dysregu-
lated secretion of insulin resulting in hypogly-
cemia (1). Most cases are attributed to defects
in pancreatic -cell ATP-sensitive K
 (KATP) channels,
which are critical for coupling glucose metabolism to
membrane electrical activity and insulin release (2,3).
KATP channels are activated (opened) by intracellular ADP
and inhibited (closed) by ATP, the product of increased
glucose metabolism. Closure of the KATP channel leads to
membrane depolarization, which activates voltage-depen-
dent Ca
2 channels, leading to an inﬂux of Ca
2 and
subsequently insulin granule exocytosis (3,4).
Cloning and reconstitution studies demonstrate that the
KATP channel is a hetero-octameric complex of two sub-
unit types: the sulfonylurea receptor (SUR)1 and the
inward rectifying K
 channel Kir6.2 (3,5,6). Given the key
role of the KATP channel in insulin secretion, it is not
surprising that inhibiting and activating mutations in the
genes encoding the subunits of this channel can result in
CHI (7,8) and neonatal diabetes (9,10), respectively. More
interestingly, a dominantly inherited SUR1 mutation has
been reported in a Finnish family, leading to CHI early in
life and impaired insulin secretion or mild diabetes in
adulthood (11,12).
Here we report a novel, de novo heterozygous mutation
in the SUR1 gene (ABCC8) (R370S) causing CHI in early
infancy followed by overt diabetes presenting at age 10.5
years, suggesting that this mutation facilitates the devel-
opment of early-onset nonautoimmune diabetes.
CASE REPORT
A female aged 10.5 years presented with fasting hypergly-
cemia (12.2 mmol/l), obesity (BMI 30.2 kg/m
2), and aggres-
sive behavior. She was the last born of noncon-
sanguineous Palestinian parents and has seven older,
healthy siblings. Both parents developed type 2 diabetes
during their 5th decade of life. Her birth weight was
signiﬁcantly large (4,950 g) despite a normal gestational
oral glucose tolerance test. From the 2nd day of life until
age 3 years, she had recurrent hypoglycemic convulsions
(blood glucose 1.9–2.7 mmol/l) that were initially treated
by intravenous glucose infusions and later by administra-
tion of sweet drinks at home. Hypoglycemia was not
documented after age 3 years, but convulsions were never
adequately controlled despite antiepileptic treatment (car-
bamazepine, hydantoin). Electroencephalogram at age 1
year revealed diffuse epileptic activity, while brain
computed tomography scan was normal. Despite nor-
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DIABETES, VOL. 57, JULY 2008 1935mal developmental milestones, her current school perfor-
mance is poor, and she behaves aggressively and uses
insulting words. Her menarche was at age 10 years.
Hyperphagia and obesity have been a concern since early
childhood.
Except for few pink striae on the abdomen, her physical
exam was unremarkable for a fully pubertal adolescent.
Laboratory investigations showed a blood glucose level of
12.2 mmol/l, moderate glucosuria, and undetectable anti-
GAD (1.0 /ml) and anti-insulin autoantibodies. Thyroid
function tests and prolactin were normal, and a mildly
elevated urinary free cortisol (299 nmol/24 h; normal 250
nmol/24 h) was easily suppressed by 90% to 37.5 nmol/24 h
after 1 day of 0.5 mg dexamethasone every 6 h. Neurolog-
ical evaluation, electroencephalogram, and brain magnetic
resonance imaging were normal. Hydantoin replacement
by topiramate achieved better epileptic control.
RESEARCH DESIGN AND METHODS
Clinical studies. Before any antidiabetes treatment, a continuous glucose
monitoring system (CGMS; Minimed, Sylmar, CA) was applied for 48 h, during
which the patient had a low-carbohydrate diet. An intravenous glucose
tolerance test (IVGTT) using 25% dextrose solution (0.5 g/kg) was performed
following a 10-h fast. Glucose and insulin levels were determined at 5, 0, 1,
3, 5, and 10 min.
Genetic studies. DNA was extracted from leukocytes of the patient, her
parents, and one brother. For the patient, all coding exons and exon/intron
boundaries of KCNJ11 and ABCC8, coding for Kir6.2 and SUR1 components
of KATP channel, respectively, were PCR ampliﬁed and sequenced as previ-
ously described (13,14). Genetic markers were used to conﬁrm parenthood,
and the relevant DNA segment was sequenced in both parents. DNA from 1
brother and 65 unrelated Jerusalem Palestinians was analyzed by a speciﬁcally
designed primer mismatch assay, which creates a new Sdu1 restriction site on
the mutant allele.
Functional studies (recombinant KATP channel experiments)
Construction of SUR1 and Kir6.2 plasmids. The R370S point mutation of
SUR1 was introduced into hamster SUR1 cDNA in the pECE plasmid using the
QuikChange site-directed mutagenesis kit (Stratagene). The mutation was
conﬁrmed by DNA sequencing (15). Mutant clones from at least two indepen-
dent PCRs were analyzed to avoid false results from undesired mutations
introduced by PCR. Rat Kir6.2 cDNA is in the pCDNAI vector.
Chemiluminescence assay. Cell surface expression level was determined
by a chemiluminescence assay using SUR1 containing a ﬂag epitope (DYKD-
DDDK) at the NH2 terminal (fSUR), as previously described (16). Brieﬂy,
COSm6 cells grown on 35-mm dishes were transfected with 0.6 g fSUR1 and
0.4 g Kir6.2 cDNA per 3 g Fugene6 at 70% conﬂuency. At 48–72 h
post-transfection, cells were ﬁxed with 2% paraformaldehyde, incubated in M2
anti-FLAG antibody (10 g/ml), then horseradish peroxidase–conjugated
anti-mouse antibody (1:1,000 dilution; Jackson Immuno Research), followed
by luminol. Luminescence signal was quantiﬁed using a Turner 20/20 lumi-
nometer.
86Rb
 efﬂux assay. COSm6 transiently expressing KATP channel subunits
were loaded with
86RbCl (1 Ci/ml) overnight. Before measurement of
86Rb

efﬂux, cells were incubated for 30 min at room temperature in Krebs-Ringer
solution with metabolic inhibitors (2.5 g/ml oligomycin and 1 mmol/l
2-deoxy-D-glucose). At selected time points, the solution was aspirated from
the cells and replaced with fresh solution. At the end of a 40-min period, cells
were lysed. The
86Rb
 in the aspirated solution and the cell lysate was
counted. The percentage efﬂux at each time point was calculated as the
cumulative counts in the aspirated solution divided by the total counts from
the solutions and the cell lysates.
Electrophysiology. Inside-out patch-clamp recording of COSm6 cells tran-
siently expressing channel subunits was performed as previously described
(4,16,17) using Axopatch 1D ampliﬁer and Clampex 9.2 software. Recordings
were made at 50 mV membrane potential in symmetrical K-INT solution
containing (in mmol/l) 140 KCl, 10 K-HEPES, and 1 K-EGTA (pH 7.3 with
KOH). For measuring MgADP, diazoxide, and glibenclamide responses, MgCl2
was added for a free concentration of 1 mmol/l. Data were analyzed using
pCLAMP software. Statistical analysis was performed with Origin 6.1 using an
independent two-population two-tailed Student’s t test.
Clinical therapeutic trials. Following the in vitro study results, oral
hypoglycemic agents repaglinide (NovoNorm, 1 mg before meals for 1 day),
and glibenclamide (5–10 mg b.i.d. for 4 consecutive days) were administered,
without insulin. Fasting and postprandial glucose levels were recorded and
compared with pretreatment values.
RESULTS
Clinical studies. As CHI was evident in infancy, contin-
uous blood glucose monitoring was performed to exclude
occult hypoglycemic episodes. The CGMS revealed 48 h of
continuous hyperglycemia (glucose 9.2–20 mmol/l) with
no hypoglycemic events (Fig. 1A). Following a 12-h fast,
while glucose was consistently high (12.2 mmol/l), insulin
was 285 pmol/l, cortisol 338 nmol/l, growth hormone 81.4
pmol/l, and ammonia 44 mol/l (reference range 10–60).
-OH-butyrate, acetoacetate, and free fatty acids were
elevated at 232, 101, and 460 mol/l, respectively. IVGTT
revealed some incremental insulin secretion, up to 582
pmol/l, that failed to restore euglycemia (Fig. 1B) but
suggested a possible role for insulin secretagogues as a
treatment modality.
Genetic analysis. The increased birth weight, recurrent
hypoglycemia, and consequent neurological damage sug-
gested neonatal hyperinsulinism despite the current re-
duced insulin secretion. A novel heterozygous missense
mutation was detected in exon 7 of ABCC8 (AGG3AGC
at the 1,111 nucleotide position) (Fig. 2A), predicting an
arginine to serine mutation at the 370th amino acid of the
SUR1 protein (R370S). Exon 7 was sequenced in both
parents’ DNA and was found to be entirely normal with no
evidence of mosaicism. One sibling and 130 alleles from
control subjects of the same ethnic background were also
negative for the mutation (Fig. 2B). Parenthood was
conﬁrmed by genetic markers.
Expression studies. To conﬁrm the functionality of our
patient’s mutation, several expression studies were per-
formed. Cotransfection of Kir6.2 and mutant SUR1 (SUR1-
R370S) in COSm6 cells demonstrated normal channel
expression on the cell membrane (Fig. 3A). The effect of
metabolic inhibition on different channel states was stud-
ied by
86Rb
 efﬂux assays. Upon metabolic inhibition,
wild-type (WT) channels were rapidly activated, giving rise
to over 90% cumulative efﬂux at the end of the 40-min
incubation period (Fig. 3B). On the other hand, the mutant
channel only gave rise to 10% efﬂux. Inside-out patch
clamp recordings revealed that the homozygote mutant
channels completely lacked response to MgADP, in con-
trast to the stimulatory effect of MgADP on WT channels
(Fig. 3C). When cells were made heterozygous by express-
ing both wild-type and mutant (WT:R370S) proteins to
imitate our clinical setting, the metabolic inhibition–in-
duced channel activity observed was greatly reduced and
MgADP-induced current was reduced by 50% of the WT
(Fig. 3D). These results corresponded with in vivo mem-
brane depolarization in the fasting state, causing hyperin-
sulinemic hypoglycemia. Similar responses were seen
when applying the KATP channel opener diazoxide, which
could reverse the inhibitory effect of 0.1 mmol/l ATP on
WT channels but failed to stimulate the homozygous
mutated channels (Fig. 3E). In the heterozygous cells
(WT:R370S), the channel was partially stimulated by dia-
zoxide (Fig. 3F). The sulfonylurea glibenclamide, given at
10 and 100 nmol/l, blocked the WT channels but also had
a similar blocking effect on the mutant channels, in
homozygous and heterozygous states (Fig. 3G and H).
Therapeutic trials by insulin secretagogues. Based on
some retained insulin response to IVGTT and the response
of the mutated channel to glibenclamide, we studied our
patient’s response to insulin secretagogues. Repaglinide (1
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distinct from sulfonylureas (18), was given before meals;
in two consecutive trials, it resulted in a decrease of
60-min postprandial glucose levels from 9.7–10.5 mmol/l to
5–8.3 mmol/l (Fig. 1C). Similarly, 5 mg glibenclamide
administered twice daily also lowered postprandial glu-
cose levels from 8.3–11 mmol/l to 7.2–7.8 mmol/l (Fig. 1D),
and a further increment in the glibenclamide dose seemed
even more effective.
DISCUSSION
Here, we report a patient with a de novo heterozygous
mutation in the SUR1 gene (R370S) resulting in congenital
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FIG. 1. Clinical studies and trials. A: Continuous subcutaneous glucose monitoring using the MiniMed CGMS Sensor. Measurements were made
every 10 s and averaged over 5 min. During 48 h, hyperglycemia was constant, with no hypoglycemic events. B: IVGTT revealing a retained,
although insufﬁcient, insulin secretion capacity and failure to restore the euglycemia. C: A therapeutic trial with 1 mg repaglinide before meals.
As an example of one out of two consecutive trials, the 2-h postprandial glucose levels following repaglinide administration decreased from
9.7–10.5 mmol/l to 5–8.3 mmol/l. D: A therapeutic trial with 5 mg glibenclamide twice daily lowered postprandial glucose levels from 8.3–11 mmol/l
to 7.2–7.8 mmol/l.
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FIG. 2. The R370S mutation. A: Sequence analysis revealed a heterozygous G3C mutation in the SUR1 gene resulting in the substitution of
arginine for serine at the 370th amino acid of SUR1 protein. B: Detection of the mutation in the proband, but not in either the parents or the
healthy sibling, by primer mismatch Sdu1 restriction analysis of PCR-ampliﬁed genomic DNA. The mutant is digested, whereas the WT is not.
Direct sequencing of DNA from both parents failed to reveal any evidence of mosaicism.
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DIABETES, VOL. 57, JULY 2008 1937hyperinsulinism followed by overt diabetes becoming ev-
ident before age 10.5 years. ABCC8 gene mutations have
been known to cause autosomal recessive and dominant
hyperinsulinism (7,11,19). Although the amino acid loca-
tion of the R370S mutation could not predict its dominant
effect, we demonstrated normal membrane expression, a
ﬁnding common to previously reported dominant SUR1
gene mutations (16,19). As the KATP channel is a hetero-
octamer containing four SUR1 subunits, a normally pro-
cessed and translocated heterozygous mutant SUR1
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FIG. 3. Expression studies. COS cells were untransfected (unt) or transiently transfected with Kir6.2 and SUR1 of WT, R370S, or WT and R370S
at 1:1 equal molar cDNA ratio (WT:R370S) and subjected to various expression and functional analyses. A: Surface expression level of KATP
channels assessed by chemiluminescence assays. The relative chemiluminescence units of untransfected, WT, and R370S samples are 234  8( n 
11), 4,788  509 (n  14), and 4,736  485 (n  15), respectively. The WT and R370S expression levels are not signiﬁcantly different (P > 0.5).
B: Channel response to metabolic inhibition assessed by
86Rb
 efﬂux assays. Untransfected cells exhibited background efﬂux (<10% in 40 min),
whereas cells expressing WT channels exhibited >90% efﬂux, which was inhibited by 1 mol/l glibenclamide. Cells expressing the R370S mutant
had near background ﬂux levels, and cells expressing a mixture of WT and R370S showed intermediate ﬂux level between WT and the mutant.
C: Representative current traces of WT and R370S channels in response to MgADP stimulation obtained by inside-out patch clamp recording. In
contrast to WT channels, which were activated by ADP, the mutant failed to be stimulated. D: Averaged response of channels to MgADP
stimulation. The current in 0.1 mmol/l ATP or 0.1 mmol/l ATP/0.5 mmol/l ADP was expressed as percentage of those observed in K-INT solution.
In 0.1 mmol/l ATP/0.5 mmol/l ADP, the percent current of WT, WT:R370S, and R370S was 64.3  7.9 (n  10), 23.4  4.7 (n  6), and 5.4  2.3
(n  7), respectively; the values of both WT:R370S and R370S are signiﬁcantly lower than that of WT (P < 0.05 and 0.005, respectively). E and
F: Same as C and D, except that channel response to diazoxide was examined. The percent current in 0.1 mmol/l ATP/0.3 mmol/l diazoxide for WT,
WT:R370S, and R370S was 43.0  5.2, 22.8  3.0, and 3.9  1.0, respectively. Again, both the simulated heterozygous and homozygous expression
conditions gave signiﬁcantly less response than WT (P < 0.001). G: Representative current traces showing channel response to 10 nmol/l
glibenclamide in K-INT. Note: The inhibition was irreversible. H: Averaged channel response to 10 or 100 nmol/l glibenclamide. The percent
current in 10 nmol/l glibenclamide was 53.3  6.0 (n  8), 70.6  8.1 (n  4), and 55.4  4.8 (n  5) for WT, WT:R370S, and R370S, respectively;
these values are not signiﬁcantly different (P > 0.1). In 100 nmol/l glibenclamide, the percent current was 34.0  4.3 (n  10), 28.4  5.3 (n 
5), and 30.9  4.3 (n  5), respectively; the values are not signiﬁcantly different (P > 0.5).
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15 of 16 of the channels on the membrane and thus may
alter their function. Conversely, mutated SUR1 proteins
that do not reach the membrane will not result in abnor-
mal channel activity in the heterozygous state because all
channels reaching the membrane would contain four
normal SUR1 subunits.
Activating SUR1 mutations were recently found to cause
neonatal diabetes without antecedent hyperinsulinemic
hypoglycemia (10). Huopio and coworkers (11,12) re-
ported a dominant inactivating ABCC8 mutation, E1506K,
that caused hyperinsulinemic hypoglycemia followed by
hypoinsulinemic diabetes; however, when compared with
our patient, nonpancreatectomized E1506K patients in
whom overt diabetes presented later, during middle age,
had mild neonatal hypoglycemia. Studies of predominantly
Ashkenazi Jews with recessive ABCC8 mutations suggest
that the natural history of the disease is one of clinical
remission despite pancreas preservation. In some cases,
the remission progressed to impairment of glucose toler-
ance (20).
While the molecular mechanisms causing ABCC8 mu-
tation-mediated CHI and neonatal diabetes have been
clariﬁed, the molecular mechanisms resulting in the pro-
gression from hyper- to hypoinsulinism are not known. A
slow, progressive loss of -cell mass due to increased
-cell apoptosis may be responsible for both the remission
in CHI and for the progression to diabetes (20–22). Inter-
estingly, the heterozygous HNF4A mutation causing ma-
turity-onset diabetes of the young (MODY1) was recently
found to cause a phenotype similar to that described here,
with transient neonatal hyperinsulinemic hypoglycemia
followed by diabetes later in life (23), implying the possi-
bility of similar underlying pathophysiology.
Our data in COS cells suggest equal biogenesis efﬁciency
(data not shown) and surface expression of the WT and
mutant R370S proteins at the plasma membrane. Thus, it is
unlikely that the decrease in functional -cell mass is
related to apoptosis induced by misfolding of the mutant
SUR1 protein, as has been suggested for neonatal diabe-
tes–associated insulin gene mutations (24). Kassem et al.
(21) have previously shown increased -cell apoptosis in
patients with recessive ABCC8 mutations. This apoptosis
could be precipitated by increased metabolic stress due to
continuous stimulation of insulin secretion, resulting in
oxidative stress–mediated apoptosis. Alternatively, apo-
ptosis could be initiated by chronically elevated cytoplas-
mic calcium levels, as have been seen in -cells of patients
with CHI (25). Studies of Kir6.2 and SUR1 knockout mouse
models yielded variable phenotypes of glucose tolerance
ranging from normoglycemia to diabetes, but this experi-
mental model also appears to be associated with increased
-cell apoptosis and progression from hypoglycemia to
diabetes, albeit at a different rate (26–29).
Regardless of the precise mechanism, enhanced apopto-
sis appears be a generic response to inactive KATP chan-
nels and not related to the speciﬁc mutation. Why then did
our patient develop diabetes at such a young age (10.5
years)? It is likely that the obesity and the early puberty
present in our case played an important role. Both factors
contribute to insulin resistance that may have unmasked
an insulin secretion defect caused by the ABCC8 mutation.
Her constant intake of sweet drinks during childhood may
have caused -cell exhaustion. Furthermore, both parents
developed type 2 diabetes during their 5th decade, sug-
gesting the presence of a relatively heavy genetic burden
for this disease. However, none of her seven older siblings
developed adolescent or early adult diabetes, and adoles-
cent-onset type 2 diabetes is rare in Palestinians despite a
high prevalence of severe obesity, making it likely that the
ABCC8 mutation contributed signiﬁcantly to both the
obesity and the diabetic phenotype.
Our in vitro ﬁndings had signiﬁcant implications for
clinical management. Initially, our patient was treated with
insulin. However, the surprising response of the mutated
R370S KATP channel to sulfonylureas in vitro suggested the
use of these medications for glycemic control. The good
response to glibenclamide enabled our patient to be
treated with oral medications rather than insulin injec-
tions, a signiﬁcant advantage given her poor compliance.
In addition, the partial response of the WT:R370S heterozy-
gous channel to diazoxide suggests that this treatment
modality might have been effective in our patient, perhaps
preventing hypoglycemia and improving the neurological
outcome. In retrospect, adequate treatment with diazoxide
might have also prevented the need for constant glucose
loading and decreased the risk of obesity, perhaps pre-
venting or delaying the onset of diabetes.
In conclusion, we describe a new de novo mutation in
the ABCC8 gene in a patient with CHI in infancy followed
by overt diabetes in childhood. This clinical phenotype
gives another perspective to the crucial role of the SUR1
protein in -cell function. The expression studies per-
formed on the mutated SUR1 conﬁrmed channel dysfunc-
tion and indicated a possible mechanism for dominant
CHI. The clinical consideration of atypical diabetes at this
young age and the in vitro studies had an important impact
on patient management, suggesting the use of oral sulfo-
nylurea treatment which resulted in improved glycemic
control. The similarity between the phenotype described
here and the phenotype related to HNF4A mutations
(MODY1) emphasizes the complex interrelationship be-
tween hyperinsulinemic hypoglycemia and early-onset hy-
poinsulinemic diabetes. Our ﬁndings suggest a critical role
for the ABCC8 R370S mutation in the early presentation of
diabetes in this patient.
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